These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622 [TBL] [Abstract][Full Text] [Related]
10. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. Schneider M; Nagashima M; Knappe S; Zhao L; Morser J; Nesheim M J Biol Chem; 2002 Mar; 277(12):9944-51. PubMed ID: 11786552 [TBL] [Abstract][Full Text] [Related]
11. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893 [TBL] [Abstract][Full Text] [Related]
12. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity. Zhao L; Buckman B; Seto M; Morser J; Nagashima M J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375 [TBL] [Abstract][Full Text] [Related]